raloxifene hydrochloride has been researched along with Pituitary Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuno, A; Okazaki, R; Okinaga, H | 1 |
1 other study(ies) available for raloxifene hydrochloride and Pituitary Neoplasms
| Article | Year |
|---|---|
High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Child; Collagen; Collagen Type I; Craniopharyngioma; Diphosphonates; Estrogens; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Hydrocortisone; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Peptides; Pituitary Neoplasms; Raloxifene Hydrochloride; Risk Factors; Testosterone; Thyroxine | 2005 |